BioSpace News Archive

Chordia Therapeutics Inc. announced that it has presented the interim results from the Phase 1 clinical trial of CTX-712, a selective pan-CDC-like kinase inhibitor discovered by Chordia, at the 2022 Annual Meeting of the American Society of Clinical Oncology, which was held from June 3 to June 7.

ECP Pharma has received a favorable, positive written response from the FDA regarding its Pre-IND submission of novel drugs for targeted indications with no clinically proven treatment options using underutilized APIs.

Oryzon Genomics, S.A. announced that it has been awarded the Seal of Excellence, a quality label awarded by the European Commission, and a non-refundable public grant of 1.87 M €.

Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced presentations at the upcoming ENDO 2022, which is being held June 11-14, 2022, in Atlanta, Georgia, USA.

Ascendis Pharma A/S (Nasdaq: ASND) today announced that its presentations at ENDO 2022 will include oral presentations of Phase 2 and Phase 3 data for its investigational product candidate TransCon PTH in adult hypoparathyroidism (HP).

Ashvattha Therapeutics announced a poster presentation of preclinical data demonstrating its hydroxyl dendrimer-based therapeutics reduce toxicity in targeted delivery to plexiform neurofibroma, a slow growing tumor associated with neurofibromatosis type 1, at the 2022 Neurofibromatosis Conference hosted by the Children’s Tumor Foundation and taking place at Loews Philadelphia Hotel in Philadelphia, PA, June 18 – 21, 2022.

Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-powered immunotherapies, announced today that it has entered into a committed equity purchase agreement (the “Agreement”) with Lincoln Park Capital Fund, LLC (“LPC”), for the issuance and sale, from time to time, of up to $40 million of its American Depositary Shares.

AbbVie (NYSE: ABBV) today announced it will present data from its migraine portfolio at the 2022 American Headache Society (AHS) Annual Scientific Meeting to be held in Denver, June 9-12.

Cytovia Therapeutics, LLC announced that Luca Scavo, CPA, MBA has been appointed as Chief Financial Officer and James Priour, MBA has been appointed as Chief Product Officer, both effective immediately.

NorthStar Medical Radioisotopes, LLC (‘NorthStar’), and Curie Therapeutics Inc., a therapeutics company dedicated to transforming cancer care with precision radiopharmaceuticals, today announced the signing of a long-term priority access supply agreement for the therapeutic medical radioisotope actinium-225 (Ac-225).